Therapy Areas: Autoimmune
InnoCare Pharma receives China IND approval for ICP-488 clinical trial
28 March 2022 -

InnoCare Pharma (HKEX: 09969), a China-based commercial stage biopharmaceutical company, announced on Sunday that it has received Investigational New Drug (IND) approval for a clinical trial from the NMPA (National Medical Products Administration) for its TYK2 JH2 allosteric inhibitor ICP-488, the firm's third innovative drug intended to treat autoimmune diseases to enter the clinical stage, in China.

The product is a potent and selective TYK2 (tyrosine kinase 2) allosteric inhibitor. It binds the JH2 domain, blocks the signal transduction of IL-23, IL-12, type 1 IFN and other inflammatory cytokine, thereby inhibiting the pathological process of autoimmune and inflammatory diseases. It will be developed to treat autoimmune diseases such as psoriasis and inflammatory bowel disease (IBD).

Dr Jasmine Cui, InnoCare co-founder, chairwoman and CEO said, 'There is a large unmet clinical need for the treatment of autoimmune diseases worldwide. InnoCare has built a strong pipeline in autoimmune diseases. With the approval of ICP-488 for clinical trials, InnoCare will further strengthen its autoimmune disease pipeline and provide better treatment options for patients with autoimmune diseases worldwide.'

Login
Username:

Password: